The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Preliminary results from the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the FRIDA study (NCT05546580), which is investigating iadademstat and gilteritinib in FLT3-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML). Preliminary results show activity of this combination in this patient population, and efforts are ongoing to find the optimal doses. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting/advisory: Rigel, Remix, Astellas, Gilead, Pfizer, Genetech, AstraZeneca, Syndax, Takeda, Schrodinger, Servier, Abbvie, BMS, Prelude; Clinical trial support: BMS, Servier, Abbvie.
